Jan Hartmann: New Transformative Treatment for Hemophilia A
Jan Hartmann, Senior Vice President, Chief Medical Officer at Haemonetics, shared a post on LinkedIn:
”Congratulations to the team led by Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa of Chugai Pharmaceutical Co., Ltd. on being awarded the 2026 Lasker-DeBakey Clinical Medical Research Award for their pioneering development of a bispecific antibody that revolutionized the treatment of Hemophilia.
First approved in 2017 and subsequently licensed by Genentech, emicizumab (Hemlibra) provided a transformative new treatment option for people living with hemophilia A.
Beyond its impact on patient care, its success demonstrated the potential of bispecific antibodies as a therapeutic platform and helped catalyze the development of this modality across a wide range of diseases.”
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 25, 2026, 17:43Jan Sloves: Femoral Vein Aneurysm and Chronic Venous Obstruction
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna RileyÖ‰ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care
-
Oct 25, 2026, 15:13Franky Biles: Celebrating Diversity and Driving Inclusion Through Representation